Manouchehri Doulabi, Ehsan http://orcid.org/0000-0003-1639-2267
Fredolini, Claudia
Gallini, Radiosa http://orcid.org/0000-0002-2709-3337
Löf, Liza
Shen, Qiujin
Ikebuchi, Ryoyo
Dubois, Louise
Azimi, Alireza
Loudig, Olivier
Gabrielsson, Susanne http://orcid.org/0000-0003-1771-1346
Landegren, Ulf http://orcid.org/0000-0002-7820-1000
Larsson, Anders http://orcid.org/0000-0003-3161-0402
Bergquist, Jonas http://orcid.org/0000-0002-4597-041X
Kamali-Moghaddam, Masood http://orcid.org/0000-0002-1303-2218
Funding for this research was provided by:
Vetenskapsrådet (2020-02258, 2018-02943, 2018-06156, 2018-02806, 2015-4870)
Torsten Söderbergs Stiftelse (M130/16)
Stiftelsen för Strategisk Forskning (SB16-0046)
Swedish Prostate Cancer Federation, Exodiab, The Swedish Cancer Foundation, The Cancer Research Foundations of Radiumhemmet
Article History
Received: 25 May 2021
Accepted: 8 December 2022
First Online: 22 December 2022
Competing interests
: Ulf Landegren is a shareholder of Navinci and Olink Proteomics, having rights to the PLA technology. Other authors declare no competing interests.